Mimetogen Pharmaceuticals is a clinical stage biotechnology company focused on developing the use of peptidomimetics as a novel approach to treating ophthalmic diseases with high unmet medical needs. The underlying technology was developed at McGill University and the Lady Davis Institute for Medical Research in Montreal.
MIM-D3, Mimetogen’s lead compound is currently being evaluated in a multi-center Phase 3 clinical study in the United States for the treatment of dry eye syndrome. In addition, the Company has developed novel therapeutic approaches for other ophthalmology indications including glaucoma and other degenerative diseases of the retina such as retinitis pigmentosa.
To successfully advance the development of its novel class of neurotrophin mimetics, Mimetogen management team has assembled a world-class group of advisors comprised of renowned experts and clinical development collaborators in the field of ophthalmology, all dedicated to the development of new therapeutic options for eye diseases that to date have only limited or no treatment or cure.